Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Augmentation for Late-Life Treatment Resistant Depression
NCT02181231Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2016
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine in major depressive disorder (MDD), sponsored by Washington University School of Medicine. Started Jun 2016; status: completed.
02
Drugs
buprenorphine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02181231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181231.